secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001641172-25-009952
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo reports Q3 net loss $1.7M; advancing IV selonabant for pediatric cannabis toxicity
--------------------------------------------------------------------------------

- Operating expenses $1.9M in Q3 fiscal 2025 vs $1.7M year ago.
- Net loss $1.7M ($0.04/share) vs $1.7M ($0.06/share) in prior year.
- Cash $13.3M plus $3M loan facility; sufficient for planned operations.
- Prioritizing IV selonabant for pediatric CNS depression; Phase 1 SAD study to start Q3 2025.
- FDA confirmed unmet need for pediatric cannabis toxicity treatment; collaboration suggested.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000164117225009952/0001641172-25-009952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000164117225009952/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer